Nature Reviews Drug Discovery is a review journal with an emphasis on drug discovery and development. With an impact factor of 28.712 in 2010 it is the leading journal in pharmacology/pharmacy and biotechnology/applied microbiology areas. The reviews are commissioned to leaders in the their specialties (non-commissioned review submissions are discouraged), but are also peer-reviewed after submission. The reviews are supplemented with glossary explanations for non-specialist readers and illustrated with figures drawn by Nature's in-house art editors. Besides reviews, the journal accepts peer-reviewed analysis articles based on existing datasets (e.g. metaanalysis), progress articles that focus on outstanding issues, and perspective articles—typically opinions or historical pieces.
In two publications in Nature Reviews Drug Discovery, Anneliene Jonker (TechMed Center) highlights the importance of health care for rare diseases, and the innovation needed in that. The personalized medicine program manager ...
Oct 25, 2023
0
0
eTRANSAFE, the European project to share data on the safety of medicines, has come to fruition. On a single platform, the project has integrated data from more than 10,000 pharmacological studies by reference pharmaceutical ...
Jun 30, 2023
0
17
In a recently published article in Nature Reviews Drug Discovery, Professor Yihai Cao's research group at the Department of Microbiology, Tumor and Cell Biology, charts information about drug development for the treatment ...
Apr 14, 2023
0
2
Autoinflammatory syndromes are often the result of genetic mutations that ultimately compromise neutrophils, macrophages and other cells of the innate immune system. Rather than showering sufferers with broad immunosuppressives, ...
A team of researchers in biomedical engineering, mechanical engineering and biomechanics in Ireland, the Netherlands and the U.S. recently developed 3-D bioprinted implants optimized with growth factors to facilitate angiogenesis—blood ...
A new study has created the most comprehensive analysis for understanding how cancer drugs work at a molecular level. Scientists at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute (EMBL-EBI) and AstraZeneca ...
Jul 7, 2020
0
163
You awake in the middle of the night from a nightmare.
Feb 10, 2020
1
976
Some diseases are like black swans. They occur so rarely that many physicians never encounter them in their clinical practice, complicating efforts to treat them.
Feb 4, 2020
1
60
Thousands of rare diseases cumulatively affect millions of people across the globe, yet because each case is so rare doctors struggle to accurately diagnose and effectively treat individual patients. Every time a patient ...
Nov 26, 2019
0
73
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase. Many patients, however, develop progressive MS at a later stage, with disability becoming ...
Aug 20, 2019
0
4
